The actual consequence of suboptimal anticoagulation management in patients with nonvalvular atrial fibrillation (NVAF) is unclear in the real-life practice.
Esther W. Chan PhD, Wallis C.Y. Lau BSc, Chung Wah Siu MD, Gregory Y.H. Lip MD, Wai K. Leung MD, Shweta Anand BDS, Kenneth K.C. Man MPH and Ian C.K. Wong PhD
Heart Rhythm, 2016-08-01, Volume 13, Issue 8, Pages 1581-1588, Copyright © 2016 Heart Rhythm Society
ANZET15 – Melbourne, 11-13 August 2015
9th Annual Australia & New Zealand Endovascular Therapies Meeting
Speaker: Alaide Chieffo, San Raffaele Scientific Institute, Milan, Italy
Duration: 27 minutes
Atrial fibrillation (AF) is the commonest cardiac arrhythmia including in end-stage renal failure patients, and there is increasing evidence that anticoagulation leads to more harm than benefit in these patients on dialysis. We reviewed the characteristics, management and outcomes of end-stage renal failure patients in dialysis with AF with a focus on warfarin anticoagulation and risk scores.
T. Wang, J. Sathananthan, C. Hood, G. Gamble, M. Marshall, A. Kerr
Heart, Lung and Circulation – Volume 23, Supplement 1, e1-e48
Abstract & full-text available.
2012 Australia and New Zealand Endovascular Therapies Meeting held in Brisbane
Speaker: Pieter Kappetein, Erasmus MC, Rotterdam, The Netherlands
Duration: 23 Minutes
2012 Annual Scientific Meeting held in Brisbane
Speaker: Claire McLintock, Auckland City Hospital, Auckland, New Zealand
Duration: 20 minutes